HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Pergola PE, Charytan C, Little DJ, et al.

Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Dialysis-Dependent CKD (DD-CKD)

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:2A 2020

BACKGROUND

Anemia in CKD is multifactorial, with contributions from reduced erythropoietin production and hepcidin-induced functional iron deficiency. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, treats anemia by enhancing erythropoietin synthesis and increasing iron availability via reducing hepcidin and increasing iron transport. We assessed the effect of roxadustat on iron parameters in patients with DD- CKD.

METHODS

Patients were randomized to open label roxadustat or epoetin alfa in 3 pivotal DD-CKD trials. Intravenous (IV) iron was administered per usual care with epoetin alfa and was limited to rescue therapy with roxadustat. Mean changes from baseline in Hb, hepcidin, and iron parameters were evaluated. Pooled results are reported.

RESULTS

Overall, 3890 patients were evaluated (roxadustat N=1943; epoetin alfa N=1947; mean baseline Hb 9.7 g/dL for both groups), including 1515 incident dialysis patients (roxadustat N=756; epoetin alfa N=759; overall mean baseline Hb values ~8.8 g/dL). Mean Hb increased more from baseline averaged over Weeks 28–52 with roxadustat vs epoetin alfa (1.21 vs 0.95 g/dL; P<0.0001). Roxadustat-treated patients used less IV iron, with mean monthly IV iron use over Weeks 28–52 of 80.3 mg for roxadustat and 108.2 mg for epoetin alfa (P<0.0001). Roxadustat reduced hepcidin and increased transferrin and serum iron; transferrin saturation did not change vs epoetin alfa (Figure). Reduction in ferritin occurred predominantly in patients with the highest baseline values when assessed by quartile (>800 µg/L).

CONCLUSION

Roxadustat facilitated iron transport and utilization by increasing both iron-carrying capacity (transferrin) and serum iron, in contrast to the effects on these parameters seen with epoetin alfa. Overall, these changes contributed to decreased need for IV iron use while achieving greater Hb increase from baseline with roxadustat vs epoetin alfa.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.